Abbott To Split Into Two Publicly Traded Companies Over Next 12 Months
This article was originally published in The Pink Sheet Daily
Executive Summary
Analysts see break-up as an effort to unlock value for proprietary pharmaceuticals unit, where expectations of slowing Humira sales may have left the company undervalued.